one-north (Biopolis / Fusionopolis)

one-north is a research-and-business estate in Singapore's Queenstown Planning Area, developed and managed by JTC Corporation, a Singapore government statutory board. Conceptualised in 1991 under the National Technology Plan and publicly announced in 1998 as a S$5 billion 'science hub,' it was officially launched on 4 December 2001, with a Zaha Hadid Architects master plan estimating S$15 billion in costs over 15–20 years. Its precincts include Biopolis (biomedical R&D, opened 2003) and Fusionopolis (infocomm, media and engineering, Phase I opened 2008), hosting A*STAR public research institutes such as the Genome Institute of Singapore alongside private R&D tenants and universities including NUS.

The 200-hectare estate now hosts over 400 companies, 15 public research institutes, 5 institutes of higher learning and more than 50,000 knowledge workers; the Fusionopolis precinct alone hosts over 90 companies and roughly 13,000 workers. Biopolis itself cost an initial S$500 million to build 18.5 hectares of lab space for 1,500+ scientists, later expanding to 13 buildings, and attracted named investments including Chugai Pharmabody Research (S$200 million over five years) and a P&G innovation centre (S$250 million). Singapore's associated biomedical manufacturing sector grew from 6,000 workers and S$6 billion output in 2000 to 15,700 workers and S$29.4 billion output in 2012. LaunchPad @ one-north has supported over 2,400 startups since 2015, including three unicorns (Carousell, PatSnap, Nium).

Independent commentary notes real limitations: despite strong manufacturing growth, few Biopolis-based biopharmaceutical spinoffs and only a couple of novel diagnostics reached market in its first decade, foreign-talent retention and a small domestic market made recouping heavy biopharma investment difficult, and Eli Lilly closed its Singapore Center for Drug Discovery in December 2010. Aggregate patent and spinoff-company counts for the estate as a whole could not be independently verified.

Read the full analysis: https://www.biospace.com/singapore-s-b-biopolis-b-a-success-story-